BURLINGAME, Calif .– (COMMERCIAL THREAD) – Humanigen, Inc. (Nasdaq: HGEN) (âHumanigenâ), a clinical-stage biopharmaceutical company focused on the prevention and treatment of an immune hyperresponse known as a âcytokine stormâ, today announced that the The Company’s Board of Directors (the âBoardâ) elected John Hohneker, MD, and Kevin Xie, PhD, as independent directors of the Company, effective October 19, 2021.
“We are excited about the depth and breadth of experience that John and Kevin will add to our board at this important time as we continue our efforts to obtain regulatory approval to market lenzilumab for the treatment of patients.” hospitalized COVID-19, while continuing our development of lenzilumab in CAR-T and other indications, âsaid Cameron Durrant, president and CEO of Humanigen.
John Hohneker, MD, has over 30 years of experience as an executive in the biopharmaceutical industry and is now a board member of five other biotechnology companies including: BioTheryX, Inc. (private); Cygnal Therapeutics, Inc. (private); Aravive, Inc. (NASDAQ: ARAV); Evelo Biosciences (NASDAQ: EVLO); and Trishula Therapeutics (private). As an executive, he has advanced several programs from preclinical evaluation to phase IV, including products in oncology and immunology. He has played a key role in the development and commercialization of many successful products, including CosentyxÂ®, GleevecÂ®, ZometaÂ®, TasignaÂ® and AfinitorÂ®. His experience includes 15 years at Novartis AG, from 2001 to 2015, where he was most recently Senior Vice President and Global Head of Development, Immunology and Dermatology. Prior to Novartis, he held several positions of increasing responsibility over a period of almost 11 years, starting with Burroughs Wellcome and then with his successor Glaxo Wellcome. Dr Hohneker received a bachelor’s degree in chemistry from Gettysburg College and a medical degree from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School. He completed his internship and residency in internal medicine and his fellowship in medical oncology, all at the University of North Carolina at Chapel Hill. In addition to his operational experience, Dr Hohneker has direct experience leading business development and licensing agreements, raising capital and serving on boards of directors through acquisitions.
Kevin Xie, PhD, has nearly twenty years of experience valuing and investing in companies across a wide range of health-related industries, first for 13 years on the buy side, then for six years in the industry where he has also demonstrated his ability to add value through operational improvements. He is the Chief Financial Officer of Gracell Biotechnologies (Nasdaq: GRCL), a global clinical-stage biopharmaceutical company dedicated to the discovery and development of breakthrough cell therapies intended to disrupt conventional approaches to CAR-T cell therapy. As Gracell’s CFO since July 2020, Dr Xie completed a cross-cycle and IPO that raised $ 340 million. Prior to Gracell, as President of Healthcare Holdings for Fosun Group, he assembled and managed a team of 20 investment professionals, who have invested more than $ 2 billion in more than 30 projects in the biotechnology sectors, pharmacy, information technology and health services. Dr Xie co-founded and was portfolio manager of Locust Walk Capital. Dr Xie previously served as Head of Healthcare Sector at Scopia Capital and Managing Director at Great Point Partners. He currently serves on the board of directors of ViewRay (Nasdaq: VRAY). Dr Xie holds a Bachelor of Science in Materials Science and Engineering from Tianjin University, an MBA in Finance from the Wharton School at the University of Pennsylvania, and a PhD in Chemistry from City New York University.
Humanigen, Inc. (Nasdaq: HGEN) (âHumanigenâ), is a clinical-stage biopharmaceutical company focused on the prevention and treatment of an immune hyperresponse known as a âcytokine stormâ. Lenzilumab is a first-class antibody that binds and neutralizes granulocyte-macrophage colony stimulating factor (GM-CSF). The results of preclinical models indicate that GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm. At the onset of the COVID-19 pandemic, an investigation showed that elevated levels of GM-CSF-secreting T cells were associated with the severity of the disease and admission to the intensive care unit. Humanigen’s Phase 3 LIVE-AIR study suggests that early intervention with lenzilumab could prevent the consequences of a true cytokine storm in hospitalized patients with COVID-19. Humanigen is developing lenzilumab as a treatment for the cytokine storm associated with CAR-T cell therapies targeting COVID-19 and CD19 and is also exploring the efficacy of lenzilumab in other inflammatory conditions such as acute graft-versus-host disease in patients receiving allogeneic hematopoietic stem cell transplantation, eosinophilic asthma and rheumatoid arthritis. For more information visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter and Facebook.
All statements other than statements of historical fact contained in this press release are forward-looking statements. Forward-looking statements reflect the current knowledge, assumptions, judgment and expectations of management regarding future performance or events. Although management believes that the expectations reflected in these statements are reasonable, they provide no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in forward-looking statements. Words such as “will”, “expect”, “intend”, “plan”, “potential”, “possible”, “goals”, “accelerate”, “continue” and similar expressions identify forward-looking statements, including: without limitation, statements regarding our plans for lenzilumab.
Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the risks inherent in our lack of profitability and our need for additional capital to grow our business; our dependence on partners to further develop our product candidates; uncertainties inherent in the development, obtaining the required regulatory authorizations and approvals and the launch of any new pharmaceutical product; the outcome of ongoing or future litigation; and the various risks and uncertainties described in the âRisk Factorsâ sections of our most recent annual and quarterly reports and other documents filed with the SEC.
All forward-looking statements are expressly qualified in their entirety by this cautionary statement. You should not rely on forward-looking statements as predictions of future events. We assume no obligation to revise or update any forward-looking statements made in this presentation to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unforeseen events, to update the reasons why actual results could differ materially from those anticipated in forward-looking statements, in each case, except as required by law.